Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“Another ADC lands in lung cancer.
On May 14, 2025, the FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for adults with previously treated, advanced non-squamous NSCLC harboring high c-Met protein overexpression (≥50% 3+ IHC).
Approved alongside the VENTANA MET (SP44) RxDx Assay as the companion diagnostic.
Based on LUMINOSITY trial (N=84):
- ORR: 35%
- Median DOR: 7.2 months
- Notable AEs: peripheral neuropathy, fatigue, ↓ appetite, edema
- Dose: 1.9 mg/kg IV q2w
This adds another option for EGFR-wt, c-Met high NSCLC—especially where targeted options remain limited. The field of antibody-drug conjugates (ADCs) continues to grow rapidly. Read more.”